老年髋部骨折患者抗栓治疗与死亡风险
这项回顾性队列研究纳入526例老年髋部骨折患者,分析抗血小板药、DOACs和VKAs与死亡的关系。1年死亡率在未抗栓、抗血小板、DOACs和VKAs组分别为14.3%、21.0%、26.4%和48.9%;完全校正后仅VKAs与死亡风险升高独立相关(HR 2.17,95%CI 1.22-3.83)。
要点
- VKAs组1年死亡率48.9%、2年61.7%,明显高于其他组。
- 完全校正后抗血小板药和DOACs的死亡风险不再显著。
- 所有抗栓治疗均与手术延迟和输血率升高相关。
核心结论
- VKAs使用与老年髋部骨折患者死亡风险显著升高相关,可能识别出预后不良的高危亚组。
研究设计与样本
- 回顾性队列研究,纳入2021年1月至2022年12月在一级创伤中心收治的髋部骨折患者共526例,中位年龄82岁,女性占69%。
主要发现
- 1年死亡率:未抗栓14.3%、抗血小板21.0%、DOACs 26.4%、VKAs 48.9%;2年分别为20.9%、30.4%、32.1%、61.7%(log-rank P < .001)。
- 完全校正后,抗血小板治疗与死亡的HR为0.71(95%CI 0.45-1.12),DOACs为0.99(95%CI 0.54-1.81),均不显著。
- 完全校正后,VKAs与死亡的HR为2.17(95%CI 1.22-3.83),仍显著。
- 所有抗栓治疗均与手术延迟和输血率升高相关,但手术延迟和输血均不能独立预测死亡。
临床怎么用
- 对使用VKAs的老年髋部骨折患者应进行仔细评估和个体化管理,识别高危人群。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antithrombotic therapy, including antiplatelet therapy, direct oral anticoagulants (DOACs), and vitamin K antagonists (VKAs), is increasingly prescribed. These therapies pose complex challenges in patients with hip fracture due to risks of bleeding, risks of thromboembolism, and their potential role as markers of frailty. However, limited real-world evidence exists regarding their risks and benefits in this population. This retrospective cohort study examines the association between antithrombotic therapy and mortality in older patients with hip fracture. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: Patients with hip fracture admitted to a level 1 trauma center between January 2021 and December 2022. METHODS: Data on clinical characteristics, antithrombotic therapy, and outcomes were collected from health records. Mortality was analyzed using Kaplan-Meier curves and Cox proportional hazards regression, adjusting for age, sex, comorbidity, functional status, surgery, kidney function, body mass index, and nursing home residency. Secondary outcomes included transfusion rates and thromboembolic events. RESULTS: Among 526 patients (median age, 82 years; 69% female), 1-year mortality rates were 14.3% for no antithrombotic therapy, 21.0% for antiplatelet therapy, 26.4% for DOACs, and 48.9% for VKAs. At 2 years, mortality rates increased to 20.9%, 30.4%, 32.1%, and 61.7%, respectively (log-rank P < .001). In the fully adjusted model, the mortality risks associated with antiplatelet therapy [hazard ratio (HR), 0.71; 95% CI, 0.45-1.12] and DOACs (HR, 0.99; 95% CI, 0.54-1.81) were no longer significant compared with patients without antithrombotic therapy, whereas VKAs remained significantly associated with increased mortality (HR, 2.17; 95% CI, 1.22-3.83). Secondary outcomes revealed that all antithrombotic therapies were linked to delayed surgery and higher transfusion rates. However, neither delayed surgery nor transfusions independently predicted mortality. CONCLUSIONS AND IMPLICATIONS: VKA use is associated with significantly higher mortality in older patients with hip fracture and may identify a subset at substantial risk of poor outcomes. These findings underscore the need for careful assessment and management of VKA users and further research to confirm these observations.
引用
- Vleeshouwers K, Bastings JJC, Brüggemann R, et al. Antithrombotic Therapy and Mortality Risk in Older Adults with Hip Fractures. J Am Med Dir Assoc. 2025. PMID: 40449534. doi:10.1016/j.jamda.2025.105690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。